Name of the Procedure:

• Common Name(s): Injection of Herzuma
• Technical/Medical Terms: Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg (HCPCS Code: Q5113)

Summary

This procedure involves injecting trastuzumab-pkrb, a biosimilar to the brand-name drug Herzuma, which is used primarily in the treatment of certain types of breast and gastric cancers. The medication is administered via an injection.

Purpose

• Medical Conditions/Problems Addressed: HER2-positive breast cancer, HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
• Goals/Expected Outcomes: The aim is to target and destroy cancer cells that exhibit the HER2 protein, slowing or stopping the progression of cancer, and potentially improving survival rates.

Indications

• Specific Symptoms/Conditions: HER2-positive breast cancer in both early-stage and metastatic stages. HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
• Patient Criteria/Factors: Patients must be diagnosed with cancers that have high levels of HER2 protein (HER2-positive). This can be determined through specific tests such as IHC (ImmunoHistoChemistry) and FISH (Fluorescent In Situ Hybridization).

Preparation

• Pre-procedure Instructions:
  • Follow the healthcare team's guidance on medications and dietary restrictions.
  • Inform the medical team of any allergies or existing health conditions.
• Diagnostic Tests/Assessments:
  • HER2 testing to confirm eligibility.
  • Blood tests and cardiac assessments might be required to ensure the patient can safely receive the medication.

Procedure Description

1. Step-by-Step Explanation:
   • The patient will be seated comfortably, and the injection site will be cleaned.
   • Herzuma (trastuzumab-pkrb) is typically administered as an intravenous injection.
   • The healthcare provider will insert a needle into a vein and administer the medication over several minutes.
2. Tools/Equipment: Syringe, Herzuma (trastuzumab-pkrb) in appropriate dosage, intravenous (IV) setup.
3. Anesthesia/Sedation: Not typically required for the injection itself.

Duration

• The injection typically takes about 30 minutes.

Setting

• Location: This procedure is usually performed in an outpatient clinic, hospital, or specialized cancer treatment center.

Personnel

• Healthcare Professionals Involved: Oncologist or a specialized nurse trained in administering intravenous cancer medications, and supporting nursing staff.

Risks and Complications

• Common Risks: Injection site reactions, fever, nausea, fatigue.
• Rare Risks: Severe allergic reactions, heart problems (e.g., heart failure), lung issues (e.g., trouble breathing).
• Management: Immediate management of allergic reactions, close monitoring of heart function, symptom management for other side effects.

Benefits

• Expected Benefits: Reduction or stabilization of tumor size, improved survival rates, and potential remission.
• Timeline: Benefits may vary; some patients might see results within a few weeks to months of regular treatment.

Recovery

• Post-procedure Care:
  • Monitoring for side effects.
  • Regular follow-up appointments to track progress and manage any side effects.
  • Adherence to prescribed medication schedule.
• Expected Recovery Time: Varies but ongoing monitoring and treatment sessions are typically required.

Alternatives

• Other Treatment Options: Other HER2-targeted therapies, chemotherapy, radiation therapy, surgical options.
• Pros and Cons: Each alternative has its own set of benefits and risks which should be discussed with a healthcare provider to tailor the best treatment plan for the patient.

Patient Experience

• During Procedure: Mild discomfort or pain from the injection. Some patients may experience flu-like symptoms.
• After Procedure: Potential side effects like fatigue, nausea, and injection site reactions. Pain management strategies and comfort measures will be discussed and provided.

By understanding each aspect of the Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg procedure, patients can be well-prepared and participate actively in their treatment plan.